Tao Lin
Welcome,         Profile    Billing    Logout  
 12 Trials 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Hongtao
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting
3
510
US
Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin
Arog Pharmaceuticals, Inc.
Newly Diagnosed FLT3 Mutated AML
11/22
11/24
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
NCT01810588: Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Active, not recruiting
2
270
US
CliniMACS® CD34 Reagent System, Fludarabine, Fludara, Fludarabine phosphate, Melphalan, anti-thymocyte globulin (rabbit), rATG, Rabbit ATG, Rituximab, Rituxan, Total Body Irradiation, TBI, Mycophenolate Mofetil, Cellcept, MMF, Tacrolimus, Prograf
Weill Medical College of Cornell University
Hematologic Malignancies
08/23
04/28
ARTEMIS, NCT04511130: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Completed
2
47
US
MT-401, zedenoleucel
Marker Therapeutics, Inc.
Acute Myeloid Leukemia, Stem Cell Transplantation
03/24
03/24
REMAIN, NCT02275533: Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, Trial

Active, not recruiting
2
82
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Clinical Observation, observation, Echocardiography, EC, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acute Myeloid Leukemia
05/24
10/25
NCT02333162: Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recruiting
1
30
US
Fludarabine Phosphate, 2-F-ara-AMP, Beneflur, SH T 586, Melphalan, Alkeran, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Total Marrow Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, HSC, HSCT, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic BMT, Tacrolimus, Advagraf, FK 506, Mycophenolate Mofetil, Cellcept, MMF, Laboratory Biomarker Analysis
University of Chicago, National Cancer Institute (NCI)
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
12/28
12/28
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NKX019-101, NCT05020678: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Active, not recruiting
1
150
US, RoW
NKX019
Nkarta, Inc.
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
03/25
12/38
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Terminated
1
27
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
01/23
04/23
NKX101-101, NCT04623944: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active, not recruiting
1
61
US
NKX101 - CAR NK cell therapy, Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Nkarta, Inc.
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
10/24
07/39
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26
Fan, Yu
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26
Wang, Xianding
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26
Song, Turun
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26
Huang, Zhongli
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26
Yin, Saifu
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26
Shang, Wenjun
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26
Zhou, Honglan
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26
Lin, Tao
NCT06114953: Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

Recruiting
4
152
RoW
Mizoribine, Mycophenolate Mofetil, Mycophenolate Acid
Lee's Pharmaceutical Limited
Kidney Transplant Immunosuppression
01/25
03/25
TTV, NCT05727709: Dynamic Changes of Torquetenovirus () Load in Chinese Renal Transplant Recipients

Recruiting
N/A
220
RoW
Tongji Hospital, Anapure BioScience, Caibo MedTech, SKM BioTech
Kidney Transplant Rejection, Kidney Transplant Infection, Virus, Immunosuppression
12/23
06/24
NCT04562051: Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients

Recruiting
N/A
100
RoW
prophylaxis regimen
West China Hospital
Kidney Transplantation, HBV
12/25
06/26

Download Options